RG
KALV

Rathbones Group’s KalVista Pharmaceuticals KALV Stock Holding History

Rathbones Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,922
Closed -$220K – 683
2026
Q1 		$220K Sell
10,922
-1,350
-11% -$21.8K ﹤0.01% 571
2025
Q4 		$198K Sell
12,272
-6,150
-33% -$81.4K ﹤0.01% 582
2025
Q3 		$224K Sell
18,422
-600
-3% -$8.29K ﹤0.01% 563
2025
Q2 		$215K Hold
19,022
– – ﹤0.01% 545
2025
Q1 		$220K Hold
19,022
– – ﹤0.01% 515
2024
Q4 		$161K Hold
19,022
– – ﹤0.01% 547
2024
Q3 		$220K Hold
19,022
– – ﹤0.01% 531
2024
Q2 		$224K Hold
19,022
– – ﹤0.01% 537
2024
Q1 		$226K Hold
19,022
– – ﹤0.01% 534
2023
Q4 		$233K Hold
19,022
– – ﹤0.01% 509
2023
Q3 		$183K Buy
+19,022
New +$194K ﹤0.01% 544

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rathbones Group's KALV Position: Q2 2026 in Review

Rathbones Group sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 10,922 shares — an estimated $220K sold.

Rathbones Group first reported a position in KALV in Q3 2023 and held it in 11 quarters. The position peaked at $233K in Q4 2023. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Rathbones Group reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Rathbones Group sold 10,922 KalVista Pharmaceuticals shares in Q2 2026, an estimated $220K.
  • Rathbones Group first reported a position in KalVista Pharmaceuticals in Q3 2023 and held it in 11 quarters.
  • Rathbones Group's KalVista Pharmaceuticals position peaked at $233K in Q4 2023.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Rathbones Group's 13F filing for Q2 2026, filed 23 Jul 2026.